JP2012502067A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502067A5
JP2012502067A5 JP2011526310A JP2011526310A JP2012502067A5 JP 2012502067 A5 JP2012502067 A5 JP 2012502067A5 JP 2011526310 A JP2011526310 A JP 2011526310A JP 2011526310 A JP2011526310 A JP 2011526310A JP 2012502067 A5 JP2012502067 A5 JP 2012502067A5
Authority
JP
Japan
Prior art keywords
group
hydrogen
halogen
alkyl
perhaloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/056519 external-priority patent/WO2010030785A2/en
Publication of JP2012502067A publication Critical patent/JP2012502067A/ja
Publication of JP2012502067A5 publication Critical patent/JP2012502067A5/ja
Pending legal-status Critical Current

Links

JP2011526310A 2008-09-10 2009-09-10 疾患の治療のためのヒスタミン受容体の複素環阻害剤 Pending JP2012502067A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9582608P 2008-09-10 2008-09-10
US61/095,826 2008-09-10
US23174909P 2009-08-06 2009-08-06
US61/231,749 2009-08-06
PCT/US2009/056519 WO2010030785A2 (en) 2008-09-10 2009-09-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (2)

Publication Number Publication Date
JP2012502067A JP2012502067A (ja) 2012-01-26
JP2012502067A5 true JP2012502067A5 (enExample) 2012-11-01

Family

ID=42005738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526310A Pending JP2012502067A (ja) 2008-09-10 2009-09-10 疾患の治療のためのヒスタミン受容体の複素環阻害剤

Country Status (14)

Country Link
US (2) US20100120741A1 (enExample)
EP (1) EP2324029A4 (enExample)
JP (1) JP2012502067A (enExample)
KR (1) KR20110095857A (enExample)
CN (1) CN102388044A (enExample)
AR (1) AR073574A1 (enExample)
AU (1) AU2009291719A1 (enExample)
CA (1) CA2735369A1 (enExample)
CL (1) CL2011000431A1 (enExample)
MX (1) MX2011002264A (enExample)
RU (1) RU2011113419A (enExample)
TW (1) TW201024297A (enExample)
UY (1) UY32111A (enExample)
WO (1) WO2010030785A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
TWI547522B (zh) 2009-07-07 2016-09-01 愛爾康研究有限公司 環氧乙烷環氧丁烷嵌段共聚物組成物
JP2013503178A (ja) * 2009-08-26 2013-01-31 サイリーン ファーマシューティカルズ インコーポレーティッド タンパク質キナーゼ調節物質としての縮合キノリン
JP2013053070A (ja) * 2009-11-06 2013-03-21 Takeda Chem Ind Ltd ジヒドロピロロキノリン誘導体
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
DE102010025786A1 (de) * 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
AU2012244549B2 (en) * 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2013039785A2 (en) 2011-09-12 2013-03-21 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP6031107B2 (ja) 2011-09-30 2016-11-24 シー・アンド・シー・リサーチ・ラボラトリーズC&C Research Laboratories 新規な複素環誘導体及びその用途
CA2850932A1 (en) * 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
CN104968200B (zh) 2013-02-01 2018-03-06 维尔斯达医疗公司 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
EP2968311A4 (en) * 2013-03-15 2016-07-20 Epigenetix Inc OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
DK3027613T3 (en) * 2013-07-25 2018-06-25 Univ Jagiellonski Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation and use thereof
US10688082B2 (en) 2015-06-11 2020-06-23 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
WO2018139876A1 (ko) 2017-01-26 2018-08-02 동화약품주식회사 신규한 [1, 2, 4] 트리아졸로 [4, 3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 bet 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2019177971A1 (en) * 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2019200500A1 (zh) 2018-04-15 2019-10-24 苏州大学张家港工业技术研究院 1,2,4-三氮唑及其制备方法
KR102822466B1 (ko) * 2018-04-27 2025-06-20 베이징 이터널 머터리얼 테크놀로지 씨오., 엘티디 유기 전계 발광 재료 및 소자
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商C&C新藥研究所 雜環衍生物及其用途
CN109705141B (zh) * 2019-02-20 2020-05-29 苏州大学 一种恶唑并喹啉类化合物及其制备方法与应用
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US12077539B2 (en) 2021-03-22 2024-09-03 Incyte Corporation Imidazole and triazole KRAS inhibitors
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
PE20241127A1 (es) 2021-07-07 2024-05-24 Incyte Corp Compuestos triciclicos como inhibidores de kras
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンkras阻害剤
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
CN116969943A (zh) * 2022-04-28 2023-10-31 轩竹生物科技股份有限公司 三并环类二酰甘油激酶抑制剂及其用途
WO2024027370A1 (zh) * 2022-08-03 2024-02-08 上海和誉生物医药科技有限公司 一种含氮三稠环prmt5抑制剂,其制备方法和药学上的用途
WO2024067433A1 (zh) * 2022-09-26 2024-04-04 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
EP4594520A2 (en) 2022-09-30 2025-08-06 Sixfold Bioscience Ltd. Compositions containing oligonucleotides with theranostic applications
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053600A (en) * 1973-03-08 1977-10-11 Sandoz, Inc. Tricyclic 1,2,4-triazolo-quinazolines
US4495187A (en) * 1982-10-18 1985-01-22 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
IN160956B (enExample) * 1982-10-18 1987-08-22 Pfizer
KR20010031983A (ko) * 1997-11-11 2001-04-16 우에노 도시오 축합 피라진 화합물
AU2002361374A1 (en) * 2001-12-21 2003-07-09 JSW-Research Forschungslabor GmbH% Pyrazolyl-substituted triazoloquinoxalines
EP2066645A2 (en) * 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2921927B1 (fr) * 2007-10-03 2012-10-12 Univ De Montpellier 1 Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers

Similar Documents

Publication Publication Date Title
JP2012502067A5 (enExample)
JP6694886B2 (ja) 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
JP2013510120A5 (enExample)
JP2010523522A5 (enExample)
JP2011511835A5 (enExample)
JP2013529196A5 (enExample)
EP2533639A1 (en) Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
JP2013505930A5 (enExample)
RU2011113419A (ru) Гетероциклические ингибиторы рецепторов гистамина для лечения заболевания
JP2018501315A5 (enExample)
JP2011500758A5 (enExample)
JP2017533968A5 (enExample)
JP2017531037A (ja) トリアゾロピリジン化合物および嚢胞性線維症の治療のための方法
JP2007529484A5 (enExample)
CN103200822A (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
JP2014511893A5 (enExample)
JP2009507909A5 (enExample)
JP2014513110A5 (enExample)
AU2015335783B2 (en) Tricyclic atropisomer compounds
JP2013523802A5 (enExample)
JP2013542261A5 (enExample)
JP2013510178A5 (enExample)
JP2010533699A5 (enExample)
JP2013542963A5 (enExample)
JP2015510942A5 (enExample)